The Food and Drug Administration issued a warning about allergy skin tests that are providing false negative results.
The problem has to do with allergenic extracts which are used during skin tests. The FDA said it became aware of instances in 2022 where false negative test results were associated with life-threatening anaphylaxis when a person was exposed to peanuts.
For people who recently received a negative skin test for food allergies, the FDA is advising them to speak with their health care provider to determine whether further testing is necessary.According to the National Institutes of Health, peanut or tree nut allergies affect about 3 million Americans. Health officials say many people never seek an evaluation by a physician and"only a few" had epinephrine available for emergency use.
Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Food fight: FDA is redefining ‘healthy’ and food industry is pushing backLess saturated fat, less sodium, less added sugar -- manufacturers say almost no packaged foods would qualify under the agency’s new rules
Weiterlesen »
Drug shipments to U.S. hold cheap generic Viagra, not opioids feared by FDAThe FDA's data from recent years on its seizure of packages containing drugs coming through international mail provides scant evidence that a significant number of opioids enter this way.
Weiterlesen »
Eisai, Biogen say FDA grants priority review for Alzheimer's drug LecanemabJapanese drugmaker Eisai Co Ltd and its U.S. partner Biogen Inc said on Monday that the U.S. Food and Drug Administration granted priority review for traditional approval of their Alzheimer's treatment Lecanemab.
Weiterlesen »
Altria buying vape maker NJOY for $2.75BAltria will buy vape-maker NJOY and absorb the company’s NJOY ACE production as the only e-vapor product with market authorizations from the U.S. Food and Drug Administration (FDA).
Weiterlesen »
FDA will review Eisai and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early JulyFDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early July
Weiterlesen »
Colorado pharmacies caught in the middle of abortion battle after FDA decisionPharmacy chains in Colorado are caught in the middle of the abortion battle after the Food and Drug Administration expanded access to abortion pills earlier this year.
Weiterlesen »